Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of GNX 5086 in healthy volunteers

Next Previous
X
Search
Trial Profile

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of GNX 5086 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GNX 5086 (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 29 Aug 2013 New trial record
    • 15 Aug 2013 Status changed from not yet recruiting to recruiting. The first volunteer has been enrolled, according to a Congenia media release.
    • 24 Jul 2013 Status changed from planning to not yet recruiting. The clinical trial application (CTA) received approval by local regulatory authorities in the Netherlands on 24 July 2013, according to a Congenia media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top